Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

RUA Life Sciences (RUA) Price & Analysis

RUA Stock Chart & Stats

GBX 28.50GBX 1.50(5.56%)
At close: 4:00 PM EDT
GBX 25GBX 27.5GBX 303 Aug17 Aug1 Sep14 Sep28 Sep12 Oct26 Oct
Day’s Range
GBX 27.25 - GBX 28.90
52-Week Range
GBX 10.90 - GBX 31.00
Previous Close
GBX 27.00
Volume
56.10K
Average Volume (3M)
158.95K
Market Cap
GBP 17.69M
Enterprise Value
GBP 6.08M
Total Cash (Recent Filing)
GBP 3.25M
Total Debt (Recent Filing)
GBP 794.00K
Price to Earnings (P/E)
―
Beta
0.09
Next Earnings
Jul 19, 2027
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialized Biomaterials Platform

The company operates across biomaterials supply, product development support, and manufacturing for medical-device customers. This integrated capability can deepen customer relationships and support recurring demand when development programs progress into regulated commercial production.

Revenue Scale And Gross Margin

Revenue has expanded substantially over the reported period while gross margin remains strong, indicating that the business can retain meaningful value from its specialized products and services. If maintained, this gross-profit base provides capacity to fund development and move toward operating profitability.

Conservative Balance Sheet

Low leverage and a substantial equity base provide financial flexibility relative to a highly indebted structure. This should reduce interest and refinancing pressure, preserve room for investment in biomaterials programs, and improve resilience while the company works toward stable earnings.

Bears Say

Operating Losses Persist

Operating profitability has not yet been established, so strong gross margin is not currently translating into sustainable earnings after operating costs. Continued EBIT losses could restrict internal funding, delay shareholder returns, and leave results sensitive to the timing of customer-program progress.

Negative Cash Generation

The business remains cash-consuming rather than self-funding, even though annual burn has improved materially from earlier periods. Persistent negative operating and free cash flow can increase reliance on external capital and constrain the pace of product development or manufacturing expansion.

Returns Remain Unsettled

Slightly negative return on equity and a modest net loss show that the company is not yet generating dependable returns on its capital base. Until earnings stabilize, the healthy balance sheet may support continuity but cannot by itself demonstrate an attractive or durable economic return.

RUA Life Sciences News

RUA FAQ

What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest share price was 10.90 p and its highest was 31.00 p in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is £17.69M.
When is RUA Life Sciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were RUA Life Sciences’s earnings last quarter?
RUA Life Sciences released its earnings results on Jun 30, 2026. The company reported -0.003 p earnings per share for the quarter.
Is RUA Life Sciences overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
RUA Life Sciences reported an EPS of -0.003 p in its last earnings report. Following the earnings report the stock price went up 7.042%.
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in GB:RUA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology